Angiopoietin-2

Angiopoietin-2 분자 정보

영어 이름Angiopoietin-2시판 약물 수1
임상 약물 수12표적 별명ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
최고 연구 개발 단계Approved
영어 이름Angiopoietin-2
표적 별명ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
시판 약물 수1
임상 약물 수12
최고 연구 개발 단계Approved

Angiopoietin-2분자 배경

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Angiopoietin-2분자 별명

ANGPT2,AGPT2,ANG2,Angiopoietin-2

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
TrebananibAMG-386; 20060439Phase 2 ClinicalAmgen Inc, Takeda Pharmaceutical Co LtdAdenocarcinoma, Clear Cell; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Kidney Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Sarcoma, Endometrial Stromal; Solid tumours; Uterine Neoplasms
상세
EXG102-031EXG102-031; EXG102-031 (rAAV-based gene therapy)Phase 2 ClinicalExegenesis Bio IncMacular Degeneration; Wet Macular Degeneration
상세
XMVA09XMVA-09; XMVA-09 (AAV载体基因治疗药物)Phase 2 ClinicalStarry GeneDiabetic macular oedema; Wet Macular Degeneration
상세
ASKG-712ASKG-712; AM-712; VIS-101Phase 2 ClinicalAskgene PharmaDiabetic macular oedema; Geographic Atrophy; Macular Degeneration; Wet Macular Degeneration
상세
Y-400Y-400Phase 2 ClinicalWuhan Yzy Biopharma Co LtdDiabetic macular oedema; Macular Degeneration; Wet Macular Degeneration
상세
ZifibancimigRO-7250284Phase 2 ClinicalF. Hoffmann-La Roche LtdMacular Degeneration
상세
BI-836880BI-836880Phase 2 ClinicalAblynx NvNeoplasms; Wet Macular Degeneration
상세
VanucizumabRG-7221; RO-5520985; B800Z06O8K (UNII code)Phase 1 ClinicalF. Hoffmann-La Roche LtdColorectal Neoplasms; Neoplasms; Solid tumours
상세
IBI-324IBI-324; OLN324Phase 1 ClinicalInnovent Biologics (Usa), IncDiabetic macular oedema; Macular Degeneration
상세
EB-105EB-105Phase 1 ClinicalEluminex Biosciences (Suzhou) LtdDiabetic macular oedema; Diabetic Retinopathy
상세
Bispecific antibody for ocular fundus(kexing)GB-10; GB10Phase 1 ClinicalShandong Kexing Bio-Products Co LtdEye Diseases; Macular Degeneration; Wet Macular Degeneration
상세
RG-6120RG-6120Phase 1 ClinicalF. Hoffmann-La Roche LtdMacular Degeneration
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
FaricimabRO-6867461; RG-7716ApprovedF. Hoffmann-La Roche Ltd, Genentech IncVabysmo, 罗视佳United StatesWet Macular Degeneration; Diabetic macular oedemaGenentech Inc2022-01-28Choroid Diseases; Choroidal Neovascularization; Diabetes Complications; Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Myopia; Polypoidal choroidal vasculopathy; Retinal Diseases; Retinal Vein Occlusion; Vision Disorders; Wet Macular Degeneration
상세

제품 리뷰

  • C***r2023-04-25
    0사람들이 좋아합니다
    We purchased His tagged Mouse/ANGPT2 Protein to run plate-based functional assays with our large molecules. It performed better than some commercial reagents from other vendors in the ELISA assays.
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 제품 리뷰
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호